RepliCel Life Sciences
OTC Bulletin Board : NCSLF

RepliCel Life Sciences

May 27, 2011 18:00 ET

Appointment of Peter Lewis to RepliCel's Board of Directors

VANCOUVER, BRITISH COLUMBIA--(Marketwire - May 27, 2011) -RepliCel Life Sciences(1)(the "Company" or "RepliCel") (OTCBB:NCSLF) announces that the Board has accepted the resignation of Matt Wayrynen as director effective May 27, 2011. The Board would like to thank Mr. Wayrynen for the valuable insight and leadership he provided during his tenure with the Company. The Board wishes him every success in his future endeavors.

The Company is pleased to announce the appointment of Peter Lewis, Chartered Accountant, to the Company's board of directors. Mr. Lewis is a partner with Lewis and Company, a firm specializing in taxation law since 1993. His areas of expertise include tax planning, acquisitions and divestitures, reorganizations and estate planning. He is a sought after educator, having taught and presented taxation courses at the Institute of Chartered Accountants of British Columbia and the Canadian Tax Foundation. He will be a valuable addition to the Company's independent board of directors.

About RepliCel Life Sciences

To properly reflect the Company's business focus, Newcastle Resources Ltd. is doing business as RepliCel Life Sciences. The Company has developed RepliCel™, a natural hair cell replication technology that has the potential to become the world's first, minimally invasive solution for androgenetic alopecia (pattern baldness) and general hair loss in men and women. RepliCel™ is based on autologous cell implantation technology that replicates a patient's hair cells from their own healthy hair follicles and, when reintroduced into areas of hair loss, the Company hopes to initiate natural hair regeneration. Patents for the technology have been issued by the European Union and Australia and are pending in other major international jurisdictions. The RepliCel™ procedure has been developed over the past nine years by the Company's recognized research scientists and medical experts – specialists in the fields of hair growth, hair biology and dermatology. Additional information on RepliCel is available at

On Behalf of the Board of Directors

Peter Jensen, Chairman of the Board

(1) Newcastle Resources Ltd. is doing business as RepliCel Life Sciences.

Notice Regarding Forward Looking Statements

This press release contains projections and forward-looking statements, as that term is defined under applicable securities laws. Statements in this press release, which are not purely historical, are forward-looking statements and can include, without limitation, statements based on current expectations involving a number of risks and uncertainties which are not guarantees of future performance of the Company such as the statement that the RepliCel™ hair cell replication technology has the potential to become the world's first minimally invasive solution for androgenetic alopecia (pattern baldness) and general hair loss in men and women. These statements are only predictions and involve known and unknown risks which may cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including: negative results from the Company's clinical trials, including that the Company's hair cell replication technology may not work as planned or may not be effective at causing the re-growth of hair follicles or the rejuvenation of damaged, miniaturized follicles; the effects of government regulation on the Company's business; the viability and marketability of the Company's hair cell replication technology; the Company's failure to successfully implement its marketing plan; the development of superior technology by the Company's competitors; the failure of consumers and the medical community to accept the Company's technology as safe and effective; risks associated with the Company's ability to obtain and protect rights to our intellectual property; risks and uncertainties associated with the Company's ability to raise additional capital; and other factors beyond the Company's control. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity or performance. Further, any forward-looking statement speaks only as of the date on which such statement is made, and, except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of such factors on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. Readers should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2010 and other periodic reports filed from time-to-time with the Securities and Exchange Commission on Edgar at and with the Canadian Securities Commissions on Sedar at

Contact Information

  • RepliCel Life Sciences
    Tammey George
    Director of Communications